» Articles » PMID: 39851513

ADAMTS13 Improves Endothelial Function and Reduces Inflammation in Diabetic Retinopathy

Overview
Journal Cells
Publisher MDPI
Date 2025 Jan 24
PMID 39851513
Authors
Affiliations
Soon will be listed here.
Abstract

The protease, a disintegrin and metalloproteinase with thrombospondin type 1 motif member 13 (ADAMTS13), known to cleave only the von Willebrand factor (VWF), has powerful regulatory effects on microvascular platelet adhesion, thrombosis, inflammation, and endothelial dysfunction. We study the protection against diabetes-induced retinal injury in experimental rats by supplementation with recombinant ADAMTS13. We compare human epiretinal membranes and vitreous samples from nondiabetic subjects and patients with proliferative diabetic retinopathy (PDR) and extend in vitro analyses with the use of various immunodetection and spectrofluorimetric methods on rat retina and human retinal glial and endothelial cell cultures. Functional studies include the assessment of the blood-retinal barrier (BRB), cell adhesion, and in vitro angiogenesis. In epiretinal membranes, endothelial cells and monocytes/macrophages express ADAMTS13. The levels of VWF, the platelet marker CD41, ADAMTS13, and the biomarkers of endothelial cell injury soluble VE-cadherin and soluble syndecan-1 are increased in PDR vitreous. ADAMTS13 is downregulated in diabetic rat retinas. The intravitreal administration of ADAMTS13 attenuates diabetes-induced BRB breakdown, the downregulation of VE-cadherin and β-catenin, and the upregulation of VWF, CD41, phospho-ERK1/2, HMGB1, VCAM-1, and ICAM-1. In Müller cells, ADAMTS13 attenuates MCP-1, MMP-9, and ROS upregulation induced by diabetic mimetic conditions. In HRMECs, ADAMTS13 attenuates the shedding of the soluble VE-cadherin and soluble syndecan-1 and the levels of phospho-ERK1/2, MCP-1, fractalkine, and ROS induced by diabetic mimetic conditions, the upregulation of ICAM-1 and VCAM-1 elicited by TNF-α, the adherence of monocytes induced by TNF-α, and VEGF-induced migration of human retinal microvascular endothelial cells. Our findings suggest that enhancing ADAMTS13 levels in situ ameliorates diabetes-induced retinal inflammation and vascular dysfunction.

References
1.
Vergouwen M, Knaup V, Roelofs J, de Boer O, Meijers J . Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage. J Thromb Haemost. 2014; 12(6):943-7. DOI: 10.1111/jth.12574. View

2.
Abu El-Asrar A, Nawaz M, Ahmad A, Dillemans L, Siddiquei M, Allegaert E . CD40 Ligand-CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. Int J Mol Sci. 2023; 24(21). PMC: 10648257. DOI: 10.3390/ijms242115582. View

3.
Fujioka M, Nakano T, Hayakawa K, Irie K, Akitake Y, Sakamoto Y . ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury. Neurol Sci. 2012; 33(5):1107-15. DOI: 10.1007/s10072-011-0913-9. View

4.
Hashimoto N, Ikuma K, Konno Y, Hirose M, Tadokoro H, Hasegawa H . DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment. J Pharmacol Sci. 2017; 135(1):29-36. DOI: 10.1016/j.jphs.2017.08.005. View

5.
Muroi C, Fujioka M, Mishima K, Irie K, Fujimura Y, Nakano T . Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage. J Thromb Haemost. 2014; 12(4):505-14. DOI: 10.1111/jth.12511. View